GT Medical Technologies Announces FDA Clearance of Expanded Indication for GammaTile Therapy

Patients with newly diagnosed malignant tumors are now eligible to receive FDA-cleared GammaTile® Therapy in addition to patients with recurrent brain tumors.

GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded indication for GammaTile® Therapy. Patients with newly diagnosed malignant brain tumors are now eligible to receive the FDA-cleared surgically targeted radiation therapy (STaRT).

https://www.businesswire.com/news/home/20200127005152/en/GT-Medical-Technologies-Announces-FDA-Clearance-Expanded